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1 Executive summary
One in four people in the world will be affected by a mental disorder at
some point in their life, and mental health problems are currently the
leading cause of global morbidity. Effectively addressing and
understanding this vast unmet need requires research that spans basic
research, all the way through to clinical/applied research. Research
deepens our knowledge of mental ill-health and its underlying
mechanisms and allows us to understand which interventions are
effective and for whom.
By setting funding levels and designing funding programs, policymakers
and funders directly influence what kind of research is being conducted,
where and by whom, and at what scale. But our understanding of the
“About US$3.7 billion a
year is spent on mental
health research worldwide,
equivalent to less than 50
cents per person.”
distribution of mental health research funding is limited, potentially
undermining the effectiveness of such investments. This report
attempts to fill that gap for the first time by mapping the global mental
health research funding landscape.
The International Alliance of Mental Health Research Funders (IAMHRF)
has analyzed over 75,000 research grants awarded by nearly 350
funders from over 35 countries, revealing for the first time the extent
and nature of mental health research funding. The analysis shows that:
• About US$3.7 billion a year is spent on mental health research
worldwide, equivalent to less than 50 cents per person.
• Mental health research spend is characterized by various inequities:
1. Most mental health research funding is awarded by and spent in
high-income countries. Of the total investment of US$18.5 billion
between 2015 and 2019, 98.6% came from high-income countries
compared to 1.4% from low- and middle-income countries. This
“Both cancer research and
infectious disease research
received more than twice
as much global investment
as mental health research.”
disparity partly reflects the distribution of funders, as 332 of the
345 funders who supported mental health research were from
high-income countries.
2. Research into mental health is underfunded compared to other
(physical) diseases. Both cancer research (19.0%) and infectious
disease research (17.5%) received more than twice as much global
investment as mental health research (7.4%). However, mental
health research received more investment than research into
metabolic diseases (3.9%) and respiratory conditions (2.3%).
Dementias were excluded from the definition of mental health
used in this study and are instead included in the neurological
research category (13.2%).
3. Specific fields of mental health research – notably self-harm and
suicide, eating, conduct, obsessive-compulsive and personality
disorders – are relatively underfunded compared to other fields such
as substance use and dependence, and depression. Research related
to substance use and dependence received the most funds at an
approximate average of US$700 million per year (or 19% of the
total), followed by depression with close to US$320 million per
year (or 9%). Eating, conduct, obsessive-compulsive and
personality disorders, and self-harm each received under US$25
million per year, or less than 1% of the total expenditure. Self-harm
and suicide account for over half of all years of life lost due to
mental illness, yet the analysis shows it received one of the lowest
levels of funding.
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4. The majority of mental health research investment is on basic
research, rather than clinical/applied research. Over half (56%) of
funded mental health research was in basic discovery science. By
contrast, the studies into prevention, diagnosis, and treatment of
mental health conditions were significantly underfunded, jointly
accounting for just 17% of global investments. Of particular
concern is the lack of investments into prevention, which
accounted for less than 7% of investments, and the evaluation of
treatments, which would include randomized controlled trials
(RCTs), only received 12% of funding.
“The young are not the




intervening at this age.”
5. The young are not the focus of mental health research investments,
despite anticipated long-term benefits of intervening at this age.
Most investments in mental health research funding were focused
on adults and compared with young people (33%) and the elderly
(5%). This is significant because around 75% of all mental illnesses
manifest by the age of 24 years, and the onset of most mood,
personality, eating and substance use conditions occur within a
small timeframe between adolescence and young adulthood.
• Mental health research funding that occurs as part of funding into
other comorbid conditions is difficult to measure and analyze.
• Different regions in the world have different defining characteristics:
1. Australia and New Zealand was the only region with a significant
increase in funding between 2015 and 2019.
2. Canada had the smallest median grant value among the examined
regions, indicating a smaller project size on average.
3. European funding was spread relatively evenly across the top five
mental health conditions (depression, autism spectrum disorders,
substance use and dependence, schizophrenia and psychosis).
4. Over three-quarters of research spend in and by low- and
middle-income countries was on basic research, with limited
domestic investment in applied research.
5. Over one-quarter of United Kingdom mental health research
funding came from philanthropy and charity fundraising sources,
the highest of any region.
6. The United States invested proportionately more than any other
region in substance use and dependence research compared to
other conditions.
Several important lessons were learnt from this baseline analysis,
including:
• Mental health research is underfunded compared to other disease
areas, in the context of disease burden. This gap should be reduced
with additional funding, rather than redistribution of existing funding
sources.
• The analysis of sociodemographic characteristics, such as gender
and race, is inhibited by a lack of reporting. Funders (and academics)
should be clearer in grant summaries, specifically noting which
sociodemographic group the research is addressing.
• The analysis of comorbidities proved to be challenging and
unsatisfactory. More robust approaches for recording, reporting and
analyzing comorbidity research should be developed.
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• Increased transparency and data sharing would improve our
understanding of the mental health research landscape. The low
level of funding observed in some sectors may, in part, be due to
incomplete data collection and/or a culture that is not accustomed to
the of sharing data among non-public organizations.
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2 Introduction
Mental health affects us all. One in four people in the world will be
affected by a mental disorder at some point in their life [1]. Around 450
million people currently live with such conditions worldwide, placing
mental disorders among the leading causes of ill-health and disability
[2].
Addressing this vast unmet need requires research, firstly, to guide an
understanding of the basic biomedical, psychological and social
processes that lead to mental ill-health, and secondly, to discover
implementable and affordable interventions that can either prevent
such ill-health or provide effective treatment options. But research “Our understanding of howmental health research





requires funding, which can be scarce and subject to competing
endeavors — everything from road building to healthcare, including
mental healthcare. For this reason, those responsible for allocating
research funds need to be cognizant of the impact of their policies on
the future of the mental health of the world’s population. By setting
funding levels and designing funding programs, policymakers and
funders directly influence what kind of research is being conducted,
where and by whom, and at what scale. Unfortunately, our
understanding of how mental health research funding is distributed is
limited, potentially undermining such investments’ effectiveness.
This report attempts to fill that gap by mapping the global mental health
research funding landscape. As such, it is the first time that funding
patterns for mental health research have been described at an
international level. The first part of the report provides more detail on
the motivation for this study, the need for collating robust evidence on
mental health research funding, and the approaches taken. Part two
then provides the study’s key findings, structured around a series of
inequities identified in the funding data. The final section offers some
reflections on the future direction of this type of study, including some
of its limitations and the critical need for funders to be willing to share
data in the future. This report is envisaged as the first in a series of
studies that map the landscape of mental health research investments,
with future studies updating the work presented here.
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3 The International Alliance of Mental Health Research Funders unites
funders on a shared mental health research agenda to save lives, improve
treatments and care for patients and their families
With over 30 member and partner organizations from around the world,






founded to increase the
impact of research
investments.”
including many non-English speaking organizations and organizations
based in low- and middle-income countries, the International Alliance
for Mental Health Research Funders (IAMHRF) was founded to increase
the impact of research investments.a Its diverse membership makes the
IAMHRF a unique alliance, and one that is ideally placed to develop an
equitable mental health research agenda. A list of members is provided
in Appendix A.
Today, the ambitions of the IAMHRF are to:
• Achieve significant coordination and alignment of research
agendas and strategies across the mental health sector.
• Make research and innovation an integral part of all efforts to
promote mental health advocacy, fight stigma and develop
effective new treatments and models of care.
Whilst the IAMHRF is focused on research funding, it is important to
acknowledge that research is but one part of a wider mental health
ecosystem. The mental health ecosystem is comprised of a wide variety
of stakeholder groups – including those who deliver mental health
services and advocacy groups – each contributing to improving
outcomes for people afflicted by mental ill-health. Mental health
research funders are a vital component of this ecosystem as the
discoveries and innovations that they support are critical for our
understanding of mental illness and the development of better
interventions and care. Unfortunately, fragmentation and siloed
operations have been a hallmark of the mental health ecosystem for
decades. The current COVID-19 crisis has laid bare the extreme need
for better mental health provision and coordination around the world.
Ultimately, the mental health and wellbeing of citizens depend on the
engagement of all key players and the astute coordination of their
efforts. This is the unique proposition of the IAMHRF: to unite research
funders and build bridges to other key stakeholder groups to create an
integrated mental health ecosystem that improves the livelihood of
those 450 million people who suffer from mental ill-health.
“Mental health research










This is the first study to focus on global mental health research
investments, and it will complement and improve our understanding of
the mental health research system. The allocation of research funding
can benefit significantly from both a landscape view of what kind of
research is being conducted and from a robust analysis of what has led
to desired outcomes and impacts. In turn, these analyses can help
advocacy initiatives and demonstrate accountability to taxpayers and
donors. Capturing and mapping data on the inputs, processes, outputs,
outcomes and impacts of research is crucial for these analyses. This
need is even more pressing in fields with a great diversity of science and
opinion, such as mental health [3].
a The IAMHRF was founded in 2010 as an informal collaborative of four mental health
research funders from Canada, the United States, and the United Kingdom. It is managed
by the Graham Boeckh Foundation (GBF).
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4 Revealing the extent and nature of mental health research funding on a
global scale for the first time
Whilst this project is the first of its kind, inasmuch as it provides a global
description of mental health research funding, it builds on pioneering
work by the UK Clinical Research Collaboration (UKCRC), the UK
charity MQ: Transforming mental health, and the European Commission
sponsored ROAMERb project, in developing approaches to capture and
map research investments. The UKCRC publishes regular reports on
“The first challenge faced
by the IAMHRF members
was to define what is
meant by ‘mental health
research’.”
health research spending, categorized using the Health Research
Classification System (HRCS), which includes mental health as a
category [4]. MQ, a mental health research charity, further explored this
mental health category in a series of analyses (2015, 2019) examining
UK funding data through the lens of specific mental health conditions
[5, 6]. In these studies, MQ developed a novel method for automatic
categorization of mental health research using natural language
processing on a large international research database of grant funding,
Dimensions, developed and maintained by Digital Science [7]. Some
level of international comparison was made possible by a study
conducted as part of the ROAMER project, which collated mental
health research funding from major funders in four countries – Finland,
France, Spain and the UK [8].
In agreeing to support this project, the first challenge faced by the
IAMHRF members was to define what is meant by ‘mental health
research’. Defining any research field is fraught with difficulties and is
inevitably a nebulous process. The IAMHRF, therefore, formed an
advisory committee (see Appendix B), to help with confirmation of
definitions and study design. The rationale for the chosen definition
“Critically, out of the scope





was that it was used in the previous studies by the UK charity MQ [6],
and that it was largely aligned with the conditions listed under mental,
behavioral, and neurodevelopmental disorders in the International
Classification of Diseases (ICD-11) with the addition of suicide and
self-harm, and in the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5). This means that research into normal psychology,
cognition and behavior is in scope, including perception, memory,
attention, learning, and social interaction. Basic biomedical studies of
the nervous system’s normal functioning are included if they study
cognition or behavior in some way. Critically, out of the scope of the
adopted definition is research into neurological and neurodegenerative
diseases such as Alzheimer’s disease, and research that is of general
health relevance (e.g., research into ‘health and wellbeing’, ‘mental and
physical health’, research into health behaviors such as diet, and
physical exercise).
b ROAMER stands for A Roadmap for Mental Health Research in Europe.
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5 The IAMHRF undertook an international study using natural language
processing to analyze over 75,000 research grants awarded by nearly 350
funders from over 35 countries
Once a definition of what constitutes mental health research was
agreed, the second challenge faced by the IAMHRF was to identify a
dataset that collated research grants. Here, the IAMHRF adopted the
“The second challenge
faced by the IAMHRF was
to identify a dataset that
collated research grants.”
approach developed by MQ in partnering with Dimensions, part of the
Digital Science group. Dimensions is a database that links a range of
scholarly information, including research grants, publications, datasets,
patents, and policy documents. Of specific interest for the current
project was the database of over 5 million grants from over 500 funders
and the approach developed by Digital Science to categorize grants.
Using natural language processing and machine learning, Digital Science
automatically assigns a consistent set of categories to all documents,
based on existing classifications systems from different countries. To
maximize the number of mental health grants identified, and as
described in the methodological Appendix C and accompanying paper
[9], three approaches were used:
• HRCS
The first was based on the use of the UKCRC HRCS, which looks
closely at the nature/type of the research in different fields,
including mental health, and further categorizes funding into eight
codes ranging from basic discovery science to prevention research.
• RCDC
The second was based on the Research, Condition, and Disease
Categorization (RCDC), a classification scheme used by the US
National Institutes of Health (NIH) that focuses on biological
function involved in human behavior across many levels of
information from molecular to systems to self-assessment which
contains several categories relevant to mental health (as described
in Table C.1 in Appendix C).c
• MQ
The third was the system developed by MQ in their 2015 and 2019
reports. This system is based on ICD-10 and DSM-5 codes related
to mental health, and it allows the field to be broken down into 17
subcategories, as well as providing a number of queries for
identifying grants that did not fall into any of these subcategories
(as described in Table C.1 in Appendix C).
To ensure that the Dimensions database had good coverage from
mental health research funders, the IAMHRF put out a call to its
“The IAMHRF put out a call
to its members and other
relevant funders asking
them to submit or update
their funded research
grants.”
members and other relevant funders asking them to submit or update
their funded research grants to Dimensions. This resulted in four
funders updating their data and a further 16 providing information for
the first time.
c The categories were: ’Anorexia’, ’Anxiety Disorders’, ’Attention Deficit Disorder (ADD)’,
’Autism’, ’Bipolar Disorder’, ’Child Abuse and Neglect Research’, ’Depression’, ’Eating Disor-
ders’, ’Major Depressive Disorder’, ’Post-Traumatic Stress Disorder (PTSD)’, ’Schizophrenia’,
’Screening And Brief Intervention For Substance Abuse’, ’Serious Mental Illness’, ’Suicide’,
’Suicide Prevention’, ’Mental Health’. Note that there is significant overlap between these
categories.
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Once the search algorithms were developed and the database was
updated, it was then possible to identify mental health research grants
in the Dimensions database and begin to analyze that subset of data.
Over 75,000 research grants awarded by just under 350 funders from
“Over 75,000 research
grants awarded by just
under 350 funders from
over 35 countries between
2015 to 2019 were
identified.”
over 35 countries between 2015 to 2019 were identified. This
accounted for about 4% of the 1.8 million grants active between 2015
and 2019 that are cataloged in the Dimensions database. As detailed in
Appendix C and the associated journal publication [9], each of these
grants was then further analyzed with information on award size
(amount funded), geography (the location of both funder and awardee),
characteristics of research participants (age groups), type of research
(basic to applied), subcategories of mental health (e.g., schizophrenia or
substance use), and source of funding (government, charity, etc.). In
addition, the scale of mental health research funding to various
measures of disease burden was examined and compared to other
diseases such as cancer and cardiovascular disease.
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6 About US$3.7 billion a year is spent on mental health research
worldwide, equivalent to less than 50 cents per person
Of the 75,956 research grants that were active between 2015 and
2019, 65,271 (or 86%) included information on the amount of funding
awarded. This totaled US$18.5 billion over the five-year period or
“Given a global population
of 7.7 billion people in
2019, this equates to a
paltry 50 cents per person
per year invested in mental
health research.”
US$3.7 billion a year. Given a global population of 7.7 billion people in
2019, this equates to a paltry 50 cents per person per year invested in
mental health research. As Figure 1 illustrates, the amount of research
funding was relatively stable over the five years that were analyzed,
even after adjusting for inflation. The slightly lower funding amount
observed in 2019 was likely due to delayed reporting, and hence is
shaded in the figure. The median award size was US$187,000, with
2.7% (1,762) of awards less than $10,000 and 0.6% (380) larger than
US$10 million.
Figure 1: Global investments in mental health research in real terms. (Data for 2019 may be an underestimate
due to lags in reporting)
Figure reproduced with permission from The Lancet Psychiatry
6.1 Over 95% of mental health research funding comes from government
The major contributor to mental health research funding worldwide is
governments. As illustrated in Figure 2, over 95% of funding originated
from public sources. This was true for all regions except the UK, where
philanthropy and charities contribute around a quarter of research
investments. Elsewhere, under 5% of funding came from philanthropy
and fundraising charities. The low level of funding from other sectors
may, in part, be due to incomplete data collection and/or a culture that
is not used to the sharing of data among non-public organizations.
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Figure 2: Global investments in mental health research by source of funding
6.2 There are important differences in the pattern of mental health research funding by
region
The map in Figure 3 provides some key information for each of the
geographical regions examined, including the total amount of research
“Australia and New Zealand
is the only region that saw
a sustained increase in
funding between 2015 and
2019.”
spending, the burden of mental ill-health (as measured through years
lived with disability and years of life lost (described in further detail
below), and unique characteristics of that funding. For example, as
already noted, in the UK one-quarter of funding comes from
philanthropy and charity fundraising, whilst Australia and New Zealand
(ANZ) is the only region that saw a sustained increase in funding
between 2015 and 2019. The median size of research grants in Canada
was smaller than in all other regions, suggesting that the country’s
investments in mental health may be fragmented, whereas, perhaps
surprisingly, LMICs made the highest proportionate investment in basic
research.
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United Kingdom
Over a quarter of United Kingdom mental health research 
funding came from philanthropy and charity fundraising 
sources
Research spending per year :  $237.1 million
Median grant size:  $404,000
% awarded by government:   74
% awarded to basic research:   46
Top 2 MH conditions:  1. Depression (9.6%)
2. Psychosis (7.4%)
Burden of mental health: 1,637,722 YLDs 
468,514 YLLS
Canada
Canada had the smallest median value of grant of the regions 
examined
Research spending per year :  $113.9 million
Median grant size:  $52,000
% awarded by government:   98
% awarded to basic research:  55
Top 2 MH conditions:  1. Depression (9.0%)
2. Substance use (8.6%)
Burden of mental health: 938,543 YLDs 
317,586 YLLS
Low-middle income countries
Over three quarters of research spend in and by LMICs was 
on basic research, with limited domestic research 
investment for applied research
Domestic research spending per year:  $52.2 million
Median grant size:  $79,000
% awarded by government:   98
% to basic research: 76
Top 2 MH conditions:  1. Depression (12.8%)
2. Substance use (5.1%)
Burden of mental health: 123,503,539 YLDs 
35,446,014 YLLS
United States
The United States invested proportionately more in substance 
use disorder research than any other region
Research spending per year : $2.76 billion
Median grant size:  $638,000
% awarded by government: 98
% to basic research: 56
Top 2 MH conditions:  1. Substance use. (23.6%)
2. Depression (8.4%)
Burden of mental health: 10,409,579 YLDs 
5,491,087 YLLS Australia & New Zealand
Australia & New Zealand was the only region with a 
significant increase in funding between 2015 and 2019
Research spending per year :  $83.2 million
Median grant size: $353,000
% awarded by government:   97
% to basic research: 49
Top 2 MH conditions:  1. Depression (13.0%)
2. Substance use (7.9%)
Burden of mental health: 803,646 YLDs 
230,405 YLLS
Europe
European funding was relatively evenly spread across the top 
five mental health conditions
Research spending per year :  $368.9 million
Median grant size:  $290,000
% awarded by government:   98
% awarded to basic research:   62
Top 2 MH conditions:  1. Depression (7.8%)
2. Autism spect. (6.8%)
Burden of mental health: 164,510,897 YLDs 
50,362,464 YLLS
Figure 3: Summary of key characteristics of the global mental health research investments by region
7 Mental health research spend is characterized by various inequities
The principal finding of this analysis of global investment in mental
health research funding is that it is characterized by five systemic
“Mental health research
funding is characterized by
five systemic inequities.”
inequities:
1. Most mental health research funding is awarded by and
spent in high-income countries.
2. Research into mental health is underfunded compared to
other (physical) diseases.
3. Specific fields of mental health research – notably suicide
and self-harm, eating, conduct, obsessive-compulsive and
personality disorders – are relatively underfunded compared
to other fields such as substance use and dependence, and
depression.
4. The majority of mental health research investment is on
basic research, rather than on clinical/applied research.
5. The young are not the focus of mental health research
investments, despite the anticipated long-term benefits of
early intervention.
Each of these inequities is examined below, including a detailed
description of the data, comparison with other analyses where they
exist, and any caveats that need to be considered when interpreting the
data.
7.1 Inequity 1: Most mental health research funding is awarded by and spent in
high-income countries
As previously illustrated in Figure 3, most mental health research
investments are made by funders in high-income countries (HICs), as
defined by the World Bank [10]. Of the total five-year investment of
“Per capita per year
investment in mental
health research in the US is
1000-times greater than in
LMICs.”
US$18.5 billion, 98.6% came from these high-income countries
compared to 1.4% from LMICs. This partly reflects the distribution of
funders on the database, where 332 of the 345 funders who support
mental health research are from HICs. Moreover, as illustrated in
Figure 4, the vast majority of that funding was received by HICs (97.6%),
while LMICs received just 2.4% of global research investments. Despite
some overseas investment, which should be welcomed, the extreme
geographical inequity of the distribution of funding per capita by region
is clear, as illustrated in Figure 5. Per capita per year investment in
mental health research in the US is 1000-times greater than in LMICs.
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Figure 4: Global investments in mental health research by country (2015-2019)
– first (blue) map is where the funding originates, the second (green) map is where the funding is received
Figure reproduced with permission from The Lancet Psychiatry
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Figure 5: Global investments in mental health research by region
This pattern confirms previous findings that the ‘10/90 gap’ observed in
total global investments in health R&D (both public and private sector)
also occurs in mental health research [11]. The notion of a 10/90 gap
was adopted by the Global Forum for Health Research in the 1990s to
highlight the observation that less than 10% of worldwide resources
devoted to health research were put towards health in LMICs, where
over 90% of all preventable deaths occurred [12]. More recently, [13]
estimated that in 2009, US$240 billion was spent on health R&D, of
which US$214 billion (90%) was invested in HICs [13]. Based on their
analysis, the authors concluded that “the persistent nature of the gap
between health R&D needs and the R&D that is presently funded and
undertaken calls for managed approaches to the allocation of scarce
health research resources.” This is significant because the prevalence of
different mental health conditions varies by region [14].
“There are important
cultural differences in the
way that mental health is
conceived, classified, and
treated in different regions
of the world.”
A further complication in interpreting these regional differences in the
data is that there are important cultural differences in the way that
mental health is conceived, classified, and treated in different regions of
the world [15]. For example, a condition may be recognized as a mental
illness in one region and not in another. This is significant for, in the
current analysis, a HIC definition of mental health has been applied
universally. Therefore, in addition to highlighting the underfunding of
mental health research in LMICs, it is important to acknowledge that
these nuanced cultural differences may not be adequately represented
in this analysis. A final point to recognize is that the ‘flow’ of funding
and knowledge is not exclusively from HICs to LMICs. The friendship
bench is an extraordinary example of an idea that was developed in
Zimbabwe but has subsequently been evaluated and adopted in
high-resource settings [16, 17]. In other words, varying resource
constraints, differences in health systems, and cultural differences mean
that mental health classifications and strategies for prevention and
intervention cannot simply be generalized across these fundamentally
different contexts. Furthermore, the potential for significant
contributions from LMICs must be recognized since severe resource
constraints have previously been shown to lead to innovative and
cost-effective solutions.
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7.2 Inequity 2: Research into mental health is underfunded compared to other (physical)
diseases




more than twice as much
investment as mental
health research.”
with other fields of health research, as determined by analysis of the
Dimensions database.d The benchmark fields were selected by the
advisory committee and illustrate that cancer and neoplasms research
and infections research, globally, received more than twice as much
investment as mental health research, but that mental health research
received more investment than research into metabolic and endocrine
diseases and respiratory conditions. The neurological category includes
the dementias that were excluded from the definition of mental health
used in this study.
Figure 6: Global investments in mental health research compared to other diseases
It is instructive to analyze how research spend relates to the burden of
disease, although, as with all benchmarking, such analysis needs to be
handled cautiously. To illuminate this further, two key indicators were
used – years lived with disability (YLD) and years of life lost (YLL). Years
lived with disability measures the number of years someone lives with a
disease, taking into account the severity of the illness. As such, it is a
measure of the burden of morbidity in a population. By comparison,
years of life lost (YLL) measures the impact of death caused by a
particular condition and is therefore a measure of premature mortality.
Although not used in this report, these two indicators are often
combined to measure disability-adjusted life years (DALYs) to produce a
combined measure of the disease’s overall burden.
A challenge faced in the current study is that data on the global burden
of disease (GBD), which is regularly updated by the Institute for Health
Metrics and Evaluation (IHME) (http://www.healthdata.org), uses a
different definition for mental health. As explained in the
d See Appendix C for a detailed description of the methodology.
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methodological Appendix C, the IMHE GBD 2017 query tool [18] was
used to search for specific conditions aligned with the definition of
mental health research used in this report. This meant excluding burden
data for Alzheimer’s and other neurological conditions, while including
substance use and self-harm (which are not within IHME’s definition of
mental health).
Using this approach, it was possible to examine whether the level of
“While cancer research
received US$775 for
every year lived with
disability that it causes,
mental health research
received only US$15.”
funding for dierent disease areas was equitable with respect to
disease burden, as summarized in Figure 7. The left-hand side of
Figure 7 provides the number of YLD, benchmarked against other
diseases. This reveals that globally, mental health conditions account
for an estimated 20% of all morbidity burden. By comparison, the
right-hand side provides the number of YLL, and here the mortality
burden is 3%. This illustrates one of the unique characteristics of
mental illness: it is a disease that severely impacts your morbidity (and
mortality indirectly through poorer physical health) but, with clear
exceptions such as suicide, does not kill you directly.e In contrast,
cardiovascular and related disease fatalities account for 20% of YLL
(right-hand side of Figure 7), compared to lower levels of severity
adjusted morbidity at 4% (left-hand side of Figure 7).
Figure 7: Burden of disease for selected health research categories compared to amount spent on research
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The most striking finding is that, unlike other disease areas, mental
health research is underfunded relative to its share of morbidity burden.
For example, while cancer research received US$755 for every YLD,
mental health research received only US$15, as summarized in Table 1. “There are clear inequities
in the distribution of
research funds by field of
investigation.”
These findings need to be interpreted with care, yet it is clear that when
one uses estimates of morbidity burden, such as the number of YLD,
there are clear inequities in the distribution of research funds by field of
investigation. From a policy viewpoint, this raises the tricky question of
whether such investments should be redistributed to create some
degree of parity, which by design would mean there are winners and
losers, or whether additional funding should be invested in mental
health research to ensure an equitable distribution of funding.
HRCS categories US$ invested per YLD
Cancer and neoplasms 755 26
Neurological 56 108
Infections 161 22
Cardiovascular, blood and stroke 77 8
Mental health 15 49
Metabolic and Endocrine 14 24
Respiratory 13 3
Patterns of disease burden and research funding vary by region, as
illustrated in Figure 8 – and described in Annex D. Though mental
health is a principal cause of YLD (morbidity) across all regions, there is
a geographical variation for YLL (mortality). Cancer and neoplasms are
the leading cause of YLL in the US, UK, Australia and New Zealand, and
Canada, as opposed to Cardiovascular / Stroke / Blood in LMICs and
Europe. Mental health was consistently underfunded (center columns)
compared to its morbidity burden (left columns) across all of the regions
analyzed.
e Indeed, it has been argued that the global burden of mental illness is underestimated
due to five main causes: overlap between psychiatric and neurological disorders; the group-
ing of suicide and self-harm as a separate category; the conflation of all chronic pain syn-
dromes with musculoskeletal disorders; exclusion of personality disorders from disease bur-
den calculations; and inadequate consideration of the contribution of severe mental illness
to mortality from associated causes.[19]
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Table 1: Ratio of annual research investments to years lived with disability (YLD) and years of life lost (YLL)
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Figure 8: Regional disease burden caused by selected health categories, compared to research spending
Infection
7.3 Inequity 3: Specific fields of mental health research – notably suicide and self-harm,
eating, conduct, obsessive-compulsive and personality disorders – are relatively
underfunded compared to other fields such as substance use and dependence, and
depression
The MQ classification system identified 17 condition-specific
categories, alongside two categories for research relevant to mental
health in general, facilitating a better understanding of how research
investments align with current mental health care. For the purpose of
“More striking is the
underfunding of self-harm
and suicide, which, despite
causing over half of years
of life lost to mental illness,
receive only a small
fraction of mental health
research funding.”
this analysis, grants that do not fall into any of the condition-specific
categories are combined into a single category called ‘not
disease-specific’. This category comprises most grants for research into
health services organization, healthy function, risk factors and
prevention, as well as studies relevant to many mental health conditions
at once such as centres and research infrastructure. As illustrated in
Figure 9, just under half of the funds went to research classified as not
disease-specific, meaning that it could not be attributed to any of the
17 disease-specific categories. Research related to substance use and
dependence received the most funds, averaging around US$700 million
per year (or 19% of the total), followed by depression with
approximately US$320 million per year (or 9%). At the other end of the
spectrum, eating, conduct, obsessive-compulsive and personality
disorders, and self-harm each received under US$25 million per year, or
less than 1% of the total expenditure.
Figure 9: Global investments in mental health research by condition
Figure reproduced with permission from The Lancet Psychiatry
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This inequity is even starker in the context of the burden of disease, as
measured through YLD and YLL in Figure 10. Depression and substance
use account for the highest levels of morbidity burden, which, to a
degree, justify current levels of research investment. More striking is
the underfunding of self-harm and suicide, which, despite causing over
half of years of life lost to mental illness, receive only a small fraction of
mental health research funding. This figure may be of specific use to
current funders of mental health research when identifying gaps that
can be effectively addressed.
Figure 10: Burden of disease for selected conditions compared to amount spent on research
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7.4 Inequity 4: The majority of mental health research investment is on basic research,
rather than on clinical/applied research
The Dimensions database captures research activity using the HRCS
Research Activity Codes (RACs), that uses an eight-point scale to
classify research along a basic to clinical/applied axis. The activity codes
are automatically assigned to health-related grants by a
machine-learning algorithm. As illustrated in Figure 11, the majority
(56%) of funded mental health research is basic, that is codes 1






for the UK for both mental health research by MQ (46%) and for all
research by UKCRC (52%). By contrast, the studies into prevention,
detection, and developing treatments (codes 3, 4 and 5) for mental
health conditions are significantly underfunded, jointly accounting for
17% of global investments. Of particular concern is the lack of
investments into prevention, which account for less than 7% of funding.
The final three codes (6, 7 and 8) cover applied research, including the
evaluation of treatments (code 6), which encompasses randomized
controlled trials (RCTs). Together, these codes account for 12% of
funding. However, as illustrated in Figure 12, there are important
regional differences. For example, the percentage of funding invested in
basic research ranges from 75% in LMICs to 47% in Australia & New
Zealand and the UK.
The balance of funding between basic and clinical research is one that
has been debated in science policy for over 75 years. One argument put
forward is that you cannot anticipate the outcomes of basic research
due to its unpredictable and serendipitous nature, and the long time it
takes for research to translate from bench to bedside. This theory was
adopted by Vannevar Bush in his influential 1945 report, The Scientific
Frontier, where he stated that “as long as they are vigorous and healthy
and their scientists are free to pursue the truth wherever it may lead,
there will be a flow of new scientific knowledge to those who can apply
it to practical problems in Government, in industry, or elsewhere” [20].
The contrasting argument is that 85% of research investments are
wasted, and that this is partly due to over-investment in basic research
[21]. This is supported by the observation that most findings in basic
research that appear to be promising either turn out to be false
positives or exaggerations. For example, in a study that examined
25,000 papers from six leading basic science journals between 1979
and 1983, 101 included claims that new discoveries had clear clinical
potential. Yet, only five resulted in interventions with licensed clinical
use by 2003, and only one of those was in regular use [22]. Similarly, in
a detailed qualitative study examining how basic mental health research
translates into applications, it was concluded that clinical research has
had a larger impact on patient care than basic research over the 20
years since the research was undertaken [23].
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Figure 11: Annual global investments in mental health research by Research Activity Code (RAC)
Figure reproduced with permission from The Lancet Psychiatry
Figure 12: Regional investments in mental health research by Research Activity Code (RAC)
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Figure 13 breaks down the type of research by various mental health
conditions. At the bottom of the figure, RACs 1 and 2 were combined
for basic research, 3, 4 and 5 for translational research and 6, 7 and 8
for applied research. What is evident from this analysis is that
schizophrenia has the highest proportion ofinvestments into basic
research (at 67%) while, perhaps not surprisingly, self-harm has the
highest proportion of applied research (66%). But perhaps the most
salient observation is again how little funding there is for prevention
research, except for prevention research into suicide and conduct
disorder.
Figure 13: Cross tabulation of the percentage of funding of dierent mental health conditions by Research
Activity Code (RAC)
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4 Detection, Screening and 
Diagnosis
7.5 Inequity 5: The young are not the focus of mental health research investments, despite
anticipated long-term benefits of intervening at this age
Age is an essential consideration in mental health, as the prevalence and
characteristics of many disorders vary significantly across the lifespan
[24]. Research can reveal effective strategies for treating mental health
“Around 75% of all mental
disorder cases manifest by
the age of 24 years, often
within a small frame of
time between adolescence
and young adulthood.”
problems in different age groups, even presenting the opportunity to
halt disorders before they develop into lifelong afflictions [25].
Around 75% of all mental disorder cases manifest by the age of 24
years, and the onset of most mood, personality, eating and substance
use conditions occur within a small frame of time between adolescence
and young adulthood [26]. Experiencing mental health problems during
this critical period of development can cause huge impairments in a
young person’s education, employment opportunities and life outcomes.
In the past decade, the benefits of early invention in mental health have
become well established, with youth mental health services widely
regarded as crucial to any successful mental health system [27, 28].
Figure 14 shows that most investments in mental health research
funding are focused on the general population, rather than on young
people (33%) and the elderly (5%). Therefore, research funding may
undervalue the impact of eliminating adult mental health problems by
intervening at a young age.
Figure 14: Distribution of research funding by age groups
However, there are three caveats to these observations. First, as
described above, the definition of mental health used in this study
excluded neurodegenerative diseases of the elderly, such as
Alzheimer’s. This may, in part, explain the relatively low levels of
funding for this age group. Second, the allocation of research grants to
these age groups is based on automated text mining of grant titles and
abstracts. This algorithm looked specifically for keywords related to the
young and the elderly and, where these could not be identified,
assumed that the research studied the general adult population. Thus,
the amount of grants corresponding to this cohort might have been
overestimated. Finally, other sociodemographic characteristics – such
as gender and race/ethnicity – cannot be analyzed as they are often not
reported in the abstracts of grant applications. This is clearly an issue
that funders (and academics) should consider addressing in the future,
as knowledge of the extent, if any, of mental health funding inequity
associated with sociodemographic variables is crucial to fully
understanding mental ill-health.
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8 Mental health research funding that occurs as part of funding into other
comorbid conditions is difficult to measure and analyze
At the outset of the project, the advisory committee was keen to
explore the relationship between mental and physical health by looking
at research that involved comorbidities – in this case, when two
conditions occur at the same time, namely a mental health condition
and another physical health condition such as cancer. This is because
most of the decreased life expectancy related to mental ill-health is due
to higher incidence and worse outcomes for comorbid physical illnesses
[29].f For example, the risk of developing cardiometabolic disease
“Physical health is worse
among people with poor
mental health.”increases by 1.4-2.0 times for those with mental health conditions
compared with the general population [29]. The relationship is
bidirectional, as physical conditions are also associated with a greater
risk of developing mental illness. Possible reasons for why physical
health is worse among people with poor mental health range from
patient distrust of the health system, discrimination, diagnostic
overshadowing, and poor coordination of care, to side effects of
psychiatric medications, and less healthy lifestyles [30, 29].
Lacking a clear precedent for identifying research grants into
comorbidity, a number of approaches were trialed (see Appendix C)
with the following strategy adopted: mental health research grants that
were additionally tagged as focused on a physical health condition
(using all HRCS codes available on Dimensions except “neuroscience”)g
and whose RAC was 2 or higher (i.e., not “Underpinning Research”,
which looks at healthy function and is thus less likely to focus on
comorbidities).
As described in the methodological Appendix C, a manual review shows
that not all grants with relevance to several conditions have comorbidity







all of the research identified investigates co-morbid mental and physical
health, it nevertheless gives an indication of where the project scope
encompasses both, and for which physical health conditions.
As illustrated in Figure 15, less than 15% of the grants were coded as
looking at mental health and another health category. Figure 16 shows
the comorbid health categories that are being investigated alongside
mental health. The most studied comorbidities were infectious disease
(US$1.18 billion, which would include e.g., mental health and HIV and
studies on infectious disease risk in substance use), cardiovascular /
stroke / blood (US$720 million, which included studies probing a link
between depression and heart failure and problems with nerves
regulating the heart in schizophrenia) and reproductive health and
childbirth (US$560 million, e.g., studies on perinatal exposure, postnatal
depression).
f It is also worth noting that the burden of disease analysis does not count mental illness’
contribution to deaths by other causes.
g Neuroscience is not used to tag comorbidity research in this analysis as we conjectured
a lot of brain research with relevance to mental health would be tagged neuroscience on
Dimensions. Counting all of these grants towards comorbidities would likely cause a huge
quantity of false positives in this analysis. Note that, by design, this approach misses grants
addressing comorbid neurological and mental health conditions - for example, depression
in Parkinson’s patients.
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Figure 15: Global investments in mental health involving other health research
Figure 16: Global investment in mental health research by comorbidities
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9 Closing Reflections
Using grant data and automated classification tools from the
Dimensions database, this report’s analysis presents the first-ever
quantitative picture of global mental health research funding. In
undertaking the analysis, a number of key lessons arise, both from a
policy viewpoint and a methodological perspective. For example, it is
evident from this analysis that mental health research is underfunded
compared to other disease areas.
From a policy viewpoint, this raises the tricky question of whether
mental health research should be given a higher priority, and if so,
whether research investments should be redistributed to create some
degree of parity. This would mean that, by design, there would be
winners and losers. Or, should additional funding be invested in mental
“It is evident from this
analysis that mental health
research is underfunded
compared to other disease
areas.”
health research to ensure an equitable distribution of funding? There is
some evidence that certain research funding sectors, including
philanthropists, are reluctant to invest in mental health. A recent report
by Future Generation and EY surveyed private funders in Australia to
better understand why they are not investing more in mental health
services and research [31]. They identified six reasons: mental illness is
complex and the mental health sector is convoluted; there is significant
duplication across mental health delivery; most mental health charities
have little profile and their messages do not resonate; measurement of
outcomes is a requirement for funding; lack of awareness of their place
in the mental health sector; and there are not enough leaders
encouraging other funders to invest in mental health. It is hoped that
the analysis presented here will give donors some reassurance that
future contributions are needed, worthwhile and impactful.
That said, in making a case for further investments in mental health
research, it is important to be mindful of and acknowledge that the data
presented in this report is biased toward the priorities of those funders
who shared their data. Contributions from both philanthropy and
industry may be under-reported due to incomplete data collection
and/or a culture that is not accustomed to sharing data among
non-public organizations. In the future, it is hoped that these issues of
data transparency and sharing can be overcome as the importance of
the type of analysis presented in this report is fully understood.
There were two further methodological issues encountered in the
analysis. Firstly, sociodemographic characteristics – such as gender and
race/ethnicity – could not be reported as they are often not described
in the abstracts of grant applications. This is clearly something that “In delivering on thesepledges, the IAMHRF and
its members can begin to
address the inequity of
mental health research
funding.”
funders and academics should consider addressing in the future. When
it comes to other sociodemographic variables, understanding the extent
of funding inequities, if they exist, is undoubtedly of public interest, as
has been highlighted during the Covid-19 pandemic. The second
methodological issue was encountered in the analysis of comorbidities,
which, as noted earlier, proved unsatisfactory due to the automated
approaches adopted. A more robust approach for recording, reporting
and analyzing comorbidities needs to be developed.
But most importantly, the quantitative analysis of global research grant
funding demonstrated several inequities that need to be addressed. To
ensure that progress is made in reducing these inequities, the IAMHRF
pledges to:
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Next Steps
• Disseminate this report widely, to various stakeholders across the
mental health sector.
• Convene research funders and mental health stakeholder groups to
ensure the data presented here are used to inform priority-setting
globally.
• Encourage further reflection and dialogue around the inequities
exposed by the analysis presented in this report.
• Advocate for greater data sharing amongst research funders from all
sectors.
• Refine existing mental health classifications, paying heed to the
diversity of cultural contexts and the voice of experts with lived
experience.
• Update the landscape analysis presented in this report as mental
health research definitions and investments evolve. In delivering on
these pledges, the IAMHRF and its members can begin to address the
inequity of mental health research funding.
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A List of IAMHRF members (current and past)
Aim Youth Mental Health (USA)
Canadian Institutes of Health Research (Canada)
Cooper Investors (Australia)
Fonds de Recherche du Québec – Santé (Canada)
Graham Boeckh Foundation (Canada)
Grand Challenges Canada (Canada)
Health Research Board (Ireland)
Janssen
Ludwig Boltzmann Gesellschaft (Austria)
Lundbeck Foundation (Denmark)
MaiTri Foundation (Australia)
Mariwala Health Initiative (India)
Meeting for Minds (Australia, Israel, Switzerland, France)
Mental Health Research Canada (Canada)
Movember (Australia)
MQ (UK)
NHS National Institute for Health Research (UK)
National Institute of Mental Health (USA)
One Mind (USA)
Philippe & Maria Halphen Foundation (France)
Society for Mental Health Research (Australia)
The Raintree Foundation (India)
Trygfonden (Denmark)
UKRI - Medical Research Council (UK)
Wellcome Trust (UK)
ZonMw (Netherlands)
Disclaimer - The views and opinions expressed in this report do not constitute
endorsement or recommendation by IAMRHF members.
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· Miranda Wolpert, Beck Smith (Wellcome Trust)
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Commission)
· Isabelle Durand-Zaleski (University of Paris XII)
• India:
· Shahid Jameel, Suveera Dhup (WT/DBT India Alliance)
• Australia:
· Marcus Nicol (National Mental Health Commission)
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C Methodological approach
As illustrated in the flow chart in Figure C.1, this study had six distinct
stages, which are described below in more detail.
Figure C.1: Overview of methodological approach
C.1 Stage 1: Defining mental health research
This study followed the definition and subcategories outlined in MQ’s
2019 analysis of mental health research funding [6]. Inclusion criteria
were aligned with the conditions listed in the Diagnostic and Statistical
Manual of Mental Disorders (DSM-5) and under mental, behavioral, and
neurodevelopmental disorders in the International Classification of
Diseases (ICD-11), with the addition of suicide and self-harm. Research
into normal psychology, cognition and behavior is also in scope,
including perception, memory, attention, learning, and social interaction.
Basic studies of the normal functioning of the nervous system are
included if they study cognition or behavior in some way. Out of scope
of this analysis is research into neurological and neurodegenerative
diseases such as Alzheimer’s disease, and research that is of general
health relevance (e.g., research into ‘health and wellbeing’, ‘mental and
physical health’, research into health behaviors such as diet, and
physical exercise).
To operationalize this definition, and as summarized in Figure C.2, three
overlapping categories were used to identify mental health research
grants from the Dimensions database. Digital Science has generated
machine learning algorithms to assign relevance scores for the Research,
Condition, and Disease Categorization system (RCDC,
https://era.nih.gov/about-era/nih-and-grantor/other/rcdc.htm) from
the US National Institutes for Health (NIH) as well as the UK Health
Research Classification System (HRCS, https://hrcsonline.net/) to all
grants in the database. HRCS has a ‘Mental Health’ category that is
aligned with the definitions outlined above. RCDC contains several
categories relevant to mental health (as listed below in Table C.1). In
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addition, the search queries originally developed by MQ were used,
which comprise 17 condition-specific search queries, as well as 11
queries designed to capture research that is relevant to mental health in
general.
Figure C.2: Grants retrieved by natural language processing categories
C.2 Stage 2: Sourcing mental health research grants
The source data for the analysis presented in this report was from the
Dimensions database created by Digital Science. Dimensions is a
database that links a range of scholarly information, including over 5
million research grants (and 1.8 million active research grants between
2015 and 2019) from over 500 funders. By using existing research
classifications systems, supplemented with natural language processing
and machine learning-based approaches, research grants can be
automatically assigned a consistent set of categories such as ‘mental
health research’. To maximize participation in the study, the IAMHRF
launched a call to 44 ofits members and partners, and to the Health
Research Alliance (HRA, https://www.healthra.org/) in January 2020,
announcing the plan for this study and supporting organizations to
submit data for the first time to the Dimensions database or to update
existing data. As a result, 16 organizations from seven countries (seven
members of the IAMHRF, four members of the HRA, and five additional
funders) made their data accessible for the first time. Of the 13
IAMHRF members whose data were already in Dimensions, nine felt
their data was up to date and four updated or added to their
information.
C.3 Stage 3: Quality assuring the data
The quality of both the approach to identifying mental health research
grants and the characteristics of those research grants were tested.
Standard metrics in information retrieval are precision and recall [32].
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Figure reproduced with permission 
from The Lancet Psychiatry
Precision is defined as the fraction of the retrieved items that are
relevant (thus equivalent to positive predictive value in diagnostics),
whereas recall is defined as the fraction of relevant items that are
retrieved out of all relevant items (thus equivalent to sensitivity).
Precision and recall were approximated in several complementary ways.
Firstly, a random subset (N = 325) of all grants included in the analysis
were reviewed, which gives an estimate of precision. Secondly, how well
the approach captures data from funders whose remit is closely aligned
to the definitions used in this study (Brain and Behavior Research
Foundation, MQ, Graham Boeckh Foundation, N = 835) was tested.
Finally, a selective sample (N = 500, of which 103 relevant to mental
health) of grants were reviewed that was constructed to contain a larger
proportion of grants from non-English speaking countries. None of
these approaches is free from bias, but in conjunction, they give a good
sense of the accuracy of the approach. In the random sample drawn
from all grants included in this analysis, precision was estimated at 76%,
which, although acceptable, could be improved in future iterations.
Recall of a set of grants from three funders that purely fund mental
health research was near perfect with 99%. In a third sample that was
weighted to be more representative of the global funding activity, recall
of mental health grants was 67%. Thus, it is likely that grants with clear
relevance to mental health will be captured with a high level of
accuracy, while in those on the periphery, there will be a significant
number of false positives and false negatives. It is not clear whether the
overall amounts are more likely to be over- or under-estimated. A
detailed description of the accuracy analysis is given in [9].
In addition, as very large grants tend to have ambiguous abstracts and
are often difficult to classify, all grants with funding amounts above
US$10m were manually reviewed, and any mistakes made by the
automated classification of these grants were corrected. Of these 497
grants, 117 were manually identified as not relevant to mental health
and excluded, which is in line with the observed precision. Additionally,
for these large grants, where necessary, mental health conditions, other
health areas and age categories were manually reassigned.
C.4 Stage 4: Analysis of data
The search strategy identified 75,956 research grants that were
classified as research on mental health. Each of these grants were then
characterised by:
1. Start and end dates
2. Amount of funding
3. Source of funding
4. Country of origin and country of spend
5. Mental health condition
6. Type of research (i.e., basic to clinical, using HRCS Research
Activity Codes)
7. Age focus of research
8. HRCS Health categories
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The approach taken for each of these is described below:
Amount of funding. Research grants awarded in a given year commonly
span across several years. In order to compute the sum of spending on
mental health research during our timeframe of interest, funding
amounts were distributed evenly across their active years. We then
counted only the fraction of the amounts allocated between 2015 to
2019. Grants that are relevant to more than one health area were split
evenly between pertinent categories, and only the share attributed to
mental health was counted. This approach is in line with the UK Health
Research Classification System [33] and the International Cancer
Research Partnership [34] in splitting between health categories and
using active years. When assigning funds to mental health
subcategories, the amounts were split evenly between disease-specific
subcategories. Currency conversions use the average annual rate for
the grant’s start year (https://www.bea.gov/).
Source of funding. Each of the 345 funders of mental health research
were manually classified according to their dominant source of funds as
government/public, philanthropy, or fundraising charity. Public funders
are government agencies or non-profit organizations that disburse
federal, state, or local government grants. Philanthropy includes
non-governmental, non-profit organizations funded through donations
from a single or very few major donors, sometimes historically resulting
in endowments today. Fundraising charities raise funds from the
general public in the form of a larger number of smaller donations. One
private for-profit industry funder and one publisher could not be
classified according to these definitions and were referred to as ‘other’
(although not reported here).
Country of origin and country of spend. Countries presented in this study
are classified according to geographical regions and economic statistics,
as defined by the World Bank [10]. All countries that did not fall into
the category of High-Income Countries (HIC) were classified as Low-
and Middle- Income Countries (LMIC). Following the European
Commission’s recommendations, Europe was defined to include the 27
countries of the European Union plus Liechtenstein, Norway, Iceland,
and Switzerland. Country of origin is the country where the funder is
located (with Belgium being used for European Commission funding),
and the country of spend is the location(s) of research institution(s)
receiving the grant.
Mental health condition. The MQ classification system defines 17
condition-specific categories, alongside two categories for research
relevant to mental health in general [7]. For the purpose of this analysis,
grants that do not fall into any of the condition-specific categories are
combined into a single category, entitled ‘not disease-specific’. This
category comprises most grants for research into health services
organization, healthy function, risk factors, and prevention, as well as
studies relevant to many mental health conditions at once, such as
centres, and research infrastructure. Table C.1 lists all approaches used
to retrieve data, and how they relate to the different subcategories.
Type of research (i.e., basic to clinical). Research was classified on a
translational spectrum using the HRCS Research Activity Codes (RACs).
This is a system of eight top-level codes, with more detailed
sub-classifications. HRCS RACs are available on Dimensions and
automatically assigned to health-related grants by a machine learning
algorithm that allows for zero, one, or multiple assignments. A
proportion of the retrieved grants (47%) were not assigned HRCS RACs
by the default model, usually because the relevance score assigned by
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the algorithm did not reach a given confidence threshold. To improve
usability for this study and to ensure all grants had a RAC assigned, the
RAC with the highest relevance score was assigned even if this was
below the threshold used in the standard implementation.
Table C.1: Queries used to identify mental health research grants and their relation to subcategories
Subcategory Rules for inclusion
1 Not disease-specific Any grants not included in any of the specific categories below, and included in HRCS
Mental Health, RCDC Mental Health, RCDC Child Abuse and Neglect Research, or any
of the 11 non-disease-specific MQ categories.
The following represents an OR relationship, i.e., a grant is counted towards a specific
category ifit falls into any one of the categories listed against it.
MQ Category RCDC Categories
2 Attention-deficit
hyperactivity disorder
ADHD Attention Deficit Disorder (ADD)




5 Bipolar disorders Bipolar Disorders Bipolar Disorder
5 Conduct disorder Conduct Disorder
7 Depression Depression Depression, Major Depressive Disorder




















Post-Traumatic Stress Disorder (PTSD)
14 Psychosis Psychosis Serious mental illness
15 Schizophrenia Schizophrenia Schizophrenia




Alcoholism*, Alcohol Use and Health*, Drug Abuse (NIDA only),
Prescription Drug Abuse, Screening And Brief Intervention For
Substance Abuse, Substance Abuse*, Substance Abuse
Prevention* *not all substance use research is within scope, therefore
not all grants with these labels will be included in the analysis but only
those identified as ‘mental health’ by one of the other categories
17 Self harm Self-Harm
18 Suicide Suicide Suicide Prevention
Table reproduced with permission from The Lancet Psychiatry
Age focus of research. Using a natural language processing algorithm
developed by Digital Science, research grants in Dimensions are coded
as being focused on young people or the elderly. Those grants that are
unassigned on this algorithm are assumed in our analysis to be focused
on the ‘general population’ cohort.
Comorbidities. From the outset of this study, research into mental
health and physical comorbidities was of keen interest to stakeholders
given the tendency for poor mental health to accompany worse
physical health outcomes and vice versa. However, grants addressing
comorbidities were not easy to identify while remaining within the
scope of this study. We considered two approaches to finding grants
relevant to physical and mental comorbidities: natural language
processing using HRCS health categories and keyword search.
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Comorbidity was defined broadly to exclude only research where one
disorder was targeted or where the grant examined multiple disorders
that were neither connected nor aecting the same patient.
We hypothesized that grants identified by machine learning as
belonging to more than one HRCS health category would have a high
probability of addressing comorbidities. We refined this approach
somewhat by not considering the “neurological” category because
grants studying a single condition are very often identified as both
“neurological” and “mental health” research. Furthermore, grants in
underpinning research are often tagged with multiple health categories
because they are potentially relevant to multiple areas of disease, so we
excluded any grants in RAC category 1 from this analysis. We, therefore,
estimated the fraction of grants investigating mental health alongside
physical health conditions by identifying grants that are part of the
mental health set, and meet the categorization threshold for a health
area other than mental health or neurological research and had a RAC
category of 2 (“aetiology”) or higher.
As an alternative strategy for identifying comorbidity grants, we applied
a keyword search to all of the grant titles and abstracts looking for
terms related to comorbidities.h
To assess the performance of these two strategies, we manually
reviewed two random samples, one for each strategy.
Manual review of 357 grants identified as about ‘comorbidities’
following the strategy using HRCS codes revealed that 52% of the
sample truly pertained to mental health and physical comorbidity. We
also manually reviewed a random sample of grants retrieved by a
keyword search for terms related to comorbidity. Of these, only 34%
were related to mental health and a physical comorbidity.
Ultimately, we chose to use the strategy based on HRCS machine
learning categories due to its better accuracy. While we cannot say
with confidence that this research investigates co-morbid mental and
physical health, it nevertheless gives an indication of where the project
scope encompasses both, and which physical health conditions are
involved. This is an area of analysis that could greatly benefit from
further refinement, which was unfortunately outside the scope of this
study.
C.5 Stage 5: Benchmarking mental health research funding against other characteristics
In addition to characterizing the actual health research grants identified
in Dimensions, comparisons were made against other research areas
indexed on Dimensions, for example, cancer and the global burden of
disease for mental health and other conditions.
The burden of disease data was obtained using the Institute for Health
Metrics and Evaluation’s (IHME) Global Burden of Disease (GBD)
Results Tool. All searches were conducted using the year 2017. A
custom search was used to select causes of death and non-fatal causes
on the GBD database that were consistent with the HRCS health
categories. The classification methodology was adapted from the UK
Clinical Research Collaboration [4] with the addition of substance use
h Search terms: comorbid* OR co-morbid* OR multimorbid* OR multi-morbid* OR poly-
morbid* OR poly-morbid* OR cooccur* OR co-occur* OR coexist* OR co-exist* OR com-
plicat* OR polymorbid* OR poly-morbid* OR multipatholog* OR multi-patholog* OR poly-
patholog* OR poly-patholog* OR multidiagnos* OR multidisor* [35]
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disorders and self-harm as disorders of mental health (see Table C.2).
Totals for years lived with disability and years of life lost in each HRCS
category were obtained by adding together the values for their
respective GBD causes.
Similarly, the comparison of spending and burden between specific
mental health conditions was achieved by matching MQ Mental Health
Categories with GBD Causes (see Table C.3). Although the categories
were generally well aligned, the absence of GBD data on personality
disorders, post-traumatic stress disorder and obsessive-compulsive
disorders prevented us from including these conditions in our burden
analysis. Regional population estimates were also obtained from the
IHME GBD 2017 study in order to calculate per-capita spending on
mental health [36].
Table C.2: Mapping HRCS health categories to Global Burden of Disease (GBD) causes
HRCS category GBD cause
Cancer B.1 Neoplasms
Cardiovascular/Stroke/Blood B.2 Cardiovascular diseases
Infection
A.1 HIV/AIDS and sexually transmitted infections
A.3 Enteric infections
A.4 Neglected tropical diseases and malaria
A.5 Other infectious diseases
Mental health
B.6 Mental disorders





B.12.5 Endocrine, metabolic, blood, and immune disorders
Neurological B.5 Neurological disorders
Respiratory A.2 Respiratory infections and tuberculosisB.3 Chronic respiratory diseases
Table C.3: Mapping of MQ Mental Health Categories onto Global Burden of Disease (GBD) causes
MQ Mental Health Category GBD Cause
Schizophrenia B.6.1 Schizophrenia
Depression B.6.2 Depressive disorders
Bipolar disorders B.6.3 Bipolar disorder
Anxiety disorders B.6.4 Anxiety disorders
Eating disorders B.6.5 Eating disorders
Autism spectrum disorders B.6.6 Autism spectrum disorders
Attention-deficit/hyperactivity disorder B.6.7 Attention-deficit/hyperactivity disorder
Conduct disorder and other disruptive behavior
disorders B.6.8 Conduct disorder
Other Neurodevelopmental Disorders 6.9 Idiopathic developmental intellectual disability
Substance use disorders B.7 Substance use disorders
Self-harm and suicide C.3.1 Self-harm
C.6 Stage 6: Sharing the data for further analysis
The quality-assured data were analyzed as described in this report and
in the accompanying paper [9]. The intention is to use this as a baseline
set of analyses that can then be updated in future years. A curated
dataset will be available to IAMHRF members, study sponsors, and
other eligible organizations.
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D Regional analysis
The following pages present regional analyses for Australia & New
Zealand (ANZ), Canada, Europe, Low- and middle-income countries
(LMICs), the United Kingdom (UK) and the United States (US). For each
region, the most salient features from the data are identified, briefly
examined, and then visualized in 5-10 relevant figures. To aid
interpretation, a similar set of data variables are studied for each region.
Still, where necessary, such as to comment on a specific feature of that
region, additional analysis may be included. The underlying data are
available for eligible organizations.
D.1 Australia & New Zealand
As illustrated in Figure D.1, Australia & New Zealand was the only
region where there was a significant – 27% – increase in funding over
the period, albeit with the largest rises occurring in the most recent
years, for which the data may be less reliable. Nevertheless, adjusting
for inflation, this is notable when compared with the other regions.
Another interesting characteristic is that mental health research
investments in Australia and New Zealand, similar to the UK, are more
strongly focused on applied RACs (i.e., 6 - Evaluation of treatments, 7-
Management of treatments and 8 - Health services). Over a third (37% -
Figure D.4) of research investments were allocated to these three codes
in Australia & New Zealand, with a similar figure in the UK (36%). In
comparison to 12% in LMICs, 23% in Europe and 26% in the US.
Canada also had a relatively high proportion at 33%.
Figure D.1: Trends in mental health research funding in Australia & New Zealand, adjusted for inflation
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Figure D.2: Mental health research funding in Australia & New Zealand by source of funding
Figure D.3: Mental health research funding in in Australia & New Zealand by specific mental health conditions
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Figure D.4: Distribution of annual mental health research funding in Australia & New Zealand by Research
Activity Code (RAC)
Figure D.5: Research funding in Australia & New Zealand for selected fields, including mental health, compared
to measures of burden of disease
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D.2 Canada
As already noted, Canada is one of four regions with declining spend on
mental health research over the period examined (Figure D.6). The other
stand-out characteristic of mental health research funding in Canada is
that the diminishing pot of funding is spread over a large number of
“Canada has the smallest
median value of grant of
the regions examined.”
grant holders meaning that Canada has the smallest median value of
grant of the regions examined. As illustrated in Table D.1, the median
grant size in Canada (across the period analyzed) was US$52,000,
which is one-twelfth of the size of the grant awarded in the US,
one-eighth of that in the UK and one-sixth of that in Europe. It is even
lower than the median size of the grant awarded in LMICs. As a result,
10% of all grants awarded in Canada are worth less than US$10,000
compared to 3.6% in Europe, 2.3% in the UK, and 0.5% in the US.
Figure D.6: Trends in mental health research funding in Canada, adjusted for inflation





Number of grants worth
less than US$10,000
Share of grants worth
less than US$10,000 (%)
ANZ 353,008 1,643 19 1.2
Canada 52,093 8,990 899 10.0
Europe 290,065 11,025 394 3.6
LMICs 78,730 8,711 69 0.8
UK 404,192 4,578 107 2.3
US 638,187 29,285 152 0.5
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Figure D.7: Mental health research funding in Canada by source of funding
Figure D.8: Mental health research funding in Canada by specific mental health conditions
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Figure D.9: Distribution of annual mental health research funding in Canada by Research Activity Code (RAC)
Figure D.10: Research funding in Canada for selected fields, including mental health, compared to measures of
burden of disease
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D.3 Europe
A particularity of the European data is the funding of the European
Commission, which comes from European Union member states at
varying proportions. European Commission funding makes up about
“A notable feature of
European funding is the
relatively even spread of
investments across the top
five conditions.”
12% of total European grants and 47% of funding in mental health
research. A notable feature of European funding is the relatively even
spread of investments across the top five conditions as illustrated in
Figure D.13. For example, the top-ranking condition in Europe,
Depression, receives just over twice as much funding as the fifth
ranking condition, Schizophrenia. By comparison, for global
investments in mental health research, the ratio was 4.31, excluding the
‘not disease-specific’ category (Table D.2).
Figure D.11: Trends in mental health research funding in Europe, adjusted for inflation
Figure D.12: Mental health research funding in Europe by source of funding
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Figure D.13: Mental health research funding in Europe by specific mental health conditions
Table D.2: Range of regional investments for top five conditions, excluding the ‘not disease-specific’ category
Region
Ratio of investment in top ranked
condition versus 5th ranked (excluding
the ‘not disease-specific’ category)
Top five conditions
ANZ 3.24
1. Depression, 2. Substance use and dependence
3. Psychosis, 4. Schizophrenia,
5. Anxiety disorders
Canada 2.83
1. Depression, 2. Substance use and dependence
3. Autism spectrum disorders, 4. Psychosis,
5. Schizophrenia.
Europe 2.09
1. Depression, 2. Autism spectrum disorders





1. Depression, 2. Autism spectrum disorders,
3. Substance use and dependence, 4. Schizophrenia,
5. Psychosis
UK 2.34
1. Depression, 2. Psychosis, 3. Schizophrenia
4. Substance use and dependence,
5. Autism spectrum disorders.
US 5.59
1. Substance use and dependence, 2. Depression
3. Autism spectrum disorders, 4. Psychosis,
5. Schizophrenia
Global 4.31
1. Substance use and dependence, 2. Depression,
3. Autism spectrum disorders, 4. Psychosis,
5. Schizophrenia
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Figure D.14: Distribution of annual mental health research funding in Europe by Research Activity Code (RAC)
Figure D.15: Research funding in Europe for selected fields, including mental health, compared to measures of
burden of disease

















Note that for ease of plotting, in Figure D.16A, European 
Commission grants are shown as funding from Belgium 
(although grant data was available, no funding amounts were 
available from national Belgian funders)
Figure D.16: European investments in mental health research by country (2015-2019)
– first (blue) map is where the funding originates, the second (green) map is where the funding is received
D.4 Low- and Middle-Income Countries
Perhaps one of the most surprising observations from this analysis was
that over three-quarters of research spend by LMICs is on basic
research with limited domestic research investment for applied
research, as illustrated in Figure D.23. Figure 4, in the main report,
“Over three-quarters of
research spending by
LMICs is on basic research”
shows the split between domestic and foreign research investments for
LMICs, i.e., those investments made by LMICs that stayed within that
country versus those that are made from HICs but occur within the
LMIC. As illustrated in Figures D.17 and D.18 about one-third (US$50
million per year) of total mental health research spending comes from
within the country and two thirds from outside (US$90 million per year).
Of the domestic spending, 76% of funded research is classified as
having RACs 1 and 2, i.e., basic research (Figure D.23), compared to
12% of applied research with RACs 6, 7 and 8. By comparison 58% of
donor investments were for basic research compared to 31% for
applied research (Figure D.24).
Figure D.17: Trends in domestic mental health research funding in LMICs, adjusted for inflation
Figure D.18: Trends in foreign mental health research funding in LMICs, adjusted for inflation
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Figure D.19: Domestic mental health research funding in LMICs by source of funding
Figure D.20: Foreign mental health research funding in LMICs by source of funding
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Figure D.21: Domestic mental health research funding in LMICs by specific mental health conditions
Figure D.22: Foreign mental health research funding in LMICs by specific mental health conditions
IAMHRF Research Report 52
Figure D.23: Distribution of annual domestic mental health research funding in LMICs by
Research Activity Code (RAC)
Figure D.24: Distribution of annual foreign mental health research expenditure in LMICs by
Research Activity Code (RAC)
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Figure D.25: Domestic research funding in LMICs for selected fields, including mental health, compared to mea-
sures of burden of disease
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D.5 United Kingdom
The most salient feature of UK mental health research funding is that a
quarter comes from philanthropy and charity fundraising sources, as
“The most salient feature of
UK mental health research




illustrated in Figure D.27. Of the US$1.15 billion invested by UK mental
health research funders between 2015 and 2019, 22% percent came
from philanthropy (which would largely be the Wellcome Trust) and a
further 4% from fundraising charities. In contrast, in all other regions,
less than 5% of funding came from these two sources. The other
feature to note is that, like in Australia & New Zealand, over one-third
(36% - Figure D.29) of research investments were allocated to RACs 6,
7 and 8 (i.e., Evaluation of treatments, Management of treatments and
Health services), i.e., applied research. This is in comparison to 12% in
LMICs, 23% in Europe and 26% in the US.
Figure D.26: Trends in mental health research funding in the UK, adjusted for inflation
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Figure D.27: Mental health research funding in the UK by source of funding
Figure D.28: Mental health research funding in the UK by specific mental health conditions
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Figure D.29: Distribution of annual mental health research funding in the UK by Research Activity Code (RAC)
Figure D.30: Research funding in the UK for selected fields, including mental health, compared to measures of
burden of disease
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D.6 United States
Most sizable investments in mental health research originate from US
funders. The stand-out feature for the US is that it invests
proportionately more in Substance use and dependence research than
any other region (Figure D.34). Overall, 24% of US mental health
“Most sizable investments
in mental health research
originate from US funders”
research funding is spent on Substance use and dependence, in
comparison to 9% in Canada, 8% in Australia & New Zealand, 5% in
Europe, 5% in LMICs and 4% in the UK. In other words, the US is
supporting 93% of all mental health research funding on Substance use
and dependence globally. This observation is further confirmed in Table
D.2 (for the regional analysis on Europe), where the ratio of the top
condition for investment to the 5th ranking one was 5.59 compared to
2.09 for Europe. That means the US is investing 5 times as much in
Substance use and dependence research than its fifth ranking condition,
Schizophrenia.
Figure D.31: Trends in mental health research funding in the US, adjusted for inflation
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Figure D.32: Mental health research funding in the US by source of funding
Figure D.33: Mental health research funding in the US by specific mental health conditions
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Figure D.34: Distribution of annual mental health research funding in the US by Research Activity Code (RAC)
Figure D.35: Research funding in the US for selected fields, including mental health, compared to measures of
burden of disease
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